Save your place

Sign in to WhoBought

Please try again later.

Agios Pharmaceuticals, Inc. (AGIO) institutional ownership

Latest close $40.06 Jul 20, 2026
Market cap$2.0B 52-week range SectorHealthcare
Funds holding · Q1 2026
226
reported AGIO position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
110 buyers · 116 sellers

Agios Pharmaceuticals, Inc. (AGIO) price and institutional activity

Dates

Q1 2026

$0 bought by 110 investors
Lynx1 Capital Management LPT. Rowe Price Investment Management, Inc. +108 more
$0 sold by 116 investors
Tcg Crossover Management, LLCCitadel Advisors LLC +114 more
Bought Sold Totals per quarter; hover a bar for the names.

Agios Pharmaceuticals, Inc. (AGIO) institutional activity · 226

Investor Type Est. change Change Δ Own Date
Lynx1 Capital Management LP · Added
Change +2.5M Date Q1 2026
Lynx1 Capital Management LP Added· Q1 2026 +2.5M Q1 2026
T. Rowe Price Investment Management, Inc. · Added
Change +1.5M Date Q1 2026
T. Rowe Price Investment Management, Inc. Added· Q1 2026 +1.5M Q1 2026
Tcg Crossover Management, LLC · Exited
Change −1.2M Δ Own −100.0% Date Q1 2026
Tcg Crossover Management, LLC Exited· Q1 2026 −1.2M −100.0% Q1 2026
D. E. Shaw & Co., Inc. · Added
Change +844K Δ Own +45.9% Date Q1 2026
D. E. Shaw & Co., Inc. Added· Q1 2026 +844K +45.9% Q1 2026
Citadel Advisors LLC Reduced· Q1 2026 −729K −54.1% Q1 2026
Capital International Investors · Reduced
Change −655K Date Q1 2026
Capital International Investors Reduced· Q1 2026 −655K Q1 2026
Balyasny Asset Management L.P. · Reduced
Change −617K Date Q1 2026
Balyasny Asset Management L.P. Reduced· Q1 2026 −617K Q1 2026
Farallon Capital Management LLC · Added
Change +524K Δ Own +10.2% Date Q1 2026
Farallon Capital Management LLC Added· Q1 2026 +524K +10.2% Q1 2026
BlackRock · Added
Change +520K Date Q1 2026
BlackRock Added· Q1 2026 +520K Q1 2026
Jane Street Group, LLC · Reduced
Change −436K Date Q1 2026
Jane Street Group, LLC Reduced· Q1 2026 −436K Q1 2026
Nuveen, LLC · Added
Change +424K Date Q1 2026
Nuveen, LLC Added· Q1 2026 +424K Q1 2026
Millennium Management LLC · Reduced
Change −366K Date Q1 2026
Millennium Management LLC Reduced· Q1 2026 −366K Q1 2026
T. Rowe Price Associates · Reduced
Change −339K Date Q1 2026
T. Rowe Price Associates Reduced· Q1 2026 −339K Q1 2026
Armistice Capital, LLC · Reduced
Change −320K Date Q1 2026
Armistice Capital, LLC Reduced· Q1 2026 −320K Q1 2026
Parkman Healthcare Partners LLC · Added
Change +304K Date Q1 2026
Parkman Healthcare Partners LLC Added· Q1 2026 +304K Q1 2026
Data through Q1 2026 · filed Jun 4, 2026
15 of 226

Famous investor activity in Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals, Inc. (AGIO) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Backstrom Jay T. · Director Exercise or conversion (M/X/C) -1K
Owned 3K Trade date Jul 8, 2026 Filed date Jul 10, 2026
Backstrom Jay T. Director Exercise or conversion (M/X/C) -1K 3K Jul 8, 2026 Jul 10, 2026
Backstrom Jay T. · Director Grant (A) 1K
Owned 1K Trade date Jul 8, 2026 Filed date Jul 10, 2026
Backstrom Jay T. Director Grant (A) 1K 1K Jul 8, 2026 Jul 10, 2026
Gheuens Sarah · Officer Sell −$151K
Price $37.56 Qty −4K Owned 85K ΔOwn −4.5% Trade date Jul 1, 2026 Filed date Jul 2, 2026
Gheuens Sarah Officer Sell $37.56 −4K −$151K 85K −4.5% Jul 1, 2026 Jul 2, 2026
Gheuens Sarah · Officer 2 operations 0
Owned 0 Trade date Jul 1, 2026 Filed date Jul 2, 2026
Gheuens Sarah Officer 2 operations 0 0 Jul 1, 2026 Jul 2, 2026
Ballal Rahul D. · Director 2 operations 0
Owned 0 Trade date Jun 18, 2026 Filed date Jun 23, 2026
Ballal Rahul D. Director 2 operations 0 0 Jun 18, 2026 Jun 23, 2026
Ballal Rahul D. · Director 2 operations 18K
Owned 15K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Ballal Rahul D. Director 2 operations 18K 15K Jun 18, 2026 Jun 23, 2026
Capello Jeffrey D. · Director 2 operations 0
Owned 0 Trade date Jun 18, 2026 Filed date Jun 23, 2026
Capello Jeffrey D. Director 2 operations 0 0 Jun 18, 2026 Jun 23, 2026
Capello Jeffrey D. · Director 2 operations 18K
Owned 15K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Capello Jeffrey D. Director 2 operations 18K 15K Jun 18, 2026 Jun 23, 2026
Foster-Cheek Kaye I. · Director 2 operations 0
Owned 0 Trade date Jun 18, 2026 Filed date Jun 23, 2026
Foster-Cheek Kaye I. Director 2 operations 0 0 Jun 18, 2026 Jun 23, 2026
Foster-Cheek Kaye I. · Director 2 operations 18K
Owned 15K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Foster-Cheek Kaye I. Director 2 operations 18K 15K Jun 18, 2026 Jun 23, 2026
Fouse Jacqualyn A. · Director 2 operations 0
Owned 0 Trade date Jun 18, 2026 Filed date Jun 23, 2026
Fouse Jacqualyn A. Director 2 operations 0 0 Jun 18, 2026 Jun 23, 2026
Fouse Jacqualyn A. · Director 2 operations 18K
Owned 15K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Fouse Jacqualyn A. Director 2 operations 18K 15K Jun 18, 2026 Jun 23, 2026
Ho Maykin · Director 2 operations 0
Owned 0 Trade date Jun 18, 2026 Filed date Jun 23, 2026
Ho Maykin Director 2 operations 0 0 Jun 18, 2026 Jun 23, 2026
Ho Maykin · Director 2 operations 18K
Owned 15K Trade date Jun 18, 2026 Filed date Jun 23, 2026
Ho Maykin Director 2 operations 18K 15K Jun 18, 2026 Jun 23, 2026
Owen Adams Catherine · Director 2 operations 0
Owned 0 Trade date Jun 18, 2026 Filed date Jun 23, 2026
Owen Adams Catherine Director 2 operations 0 0 Jun 18, 2026 Jun 23, 2026
15 of 100
15 of 100 Sign in to continue to older insider transactions.

Agios Pharmaceuticals, Inc. (AGIO) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Vanguard Group Inc 5.6M
% of shares outstanding 10.0% Filing date Feb 12, 2024
Vanguard Group Inc 5.6M 10.0% Feb 12, 2024
BlackRock Inc. 5.0M
% of shares outstanding 8.9% Filing date Jan 25, 2024
BlackRock Inc. 5.0M 8.9% Jan 25, 2024
Bb Biotech AG 4.0M
% of shares outstanding 7.2% Filing date Feb 13, 2024
Bb Biotech AG 4.0M 7.2% Feb 13, 2024
Vanguard Capital Management LLC 3.1M
% of shares outstanding 5.3% Filing date Apr 29, 2026
Vanguard Capital Management LLC 3.1M 5.3% Apr 29, 2026
D. E. Shaw & Co., L.P. 3.0M
% of shares outstanding 5.1% Filing date Jul 2, 2026
D. E. Shaw & Co., L.P. 3.0M 5.1% Jul 2, 2026
Lynx1 Capital Management LP 3.0M
% of shares outstanding 5.1% Filing date May 6, 2026
Lynx1 Capital Management LP 3.0M 5.1% May 6, 2026
State Street Corp
% of shares outstanding 4.7% Filing date Jan 22, 2024
State Street Corp 4.7% Jan 22, 2024
Armistice Capital, LLC 2.7M
% of shares outstanding 4.6% Filing date May 15, 2026
Armistice Capital, LLC 2.7M 4.6% May 15, 2026
8 of 15

Agios Pharmaceuticals, Inc. (AGIO) ownership FAQ

Who owns AGIO?

226 reporting institutions disclosed AGIO position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.